Galapagos Reports 96% CR Rate for GLPG5101 in MCL Patients at ASH 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 08 2025
0mins
Should l Buy GLPG?
Source: Newsfilter
- Significant Efficacy: In the ATALANTA-1 study, GLPG5101 achieved a 100% objective response rate among 24 treated MCL patients, with 96% attaining complete response, highlighting the therapy's robust efficacy and potential market appeal.
- Rapid Treatment: The vein-to-vein time for GLPG5101 is only 7 days, significantly reducing the dropout rate to 4% and eliminating the need for bridging therapy, thereby enhancing treatment accessibility for more patients.
- Good Safety Profile: Among 24 patients, GLPG5101 demonstrated a favorable safety profile with no Grade ≥ 3 cytokine release syndrome observed and only one case of Grade ≥ 3 neurological adverse events, indicating its safety in clinical applications.
- Strategic Shift: Galapagos intends to wind down its cell therapy activities while continuing clinical studies and considering acquisition proposals, reflecting the company's adaptability and forward-looking strategy during its transformation process.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GLPG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GLPG
Wall Street analysts forecast GLPG stock price to fall
4 Analyst Rating
1 Buy
1 Hold
2 Sell
Hold
Current: 33.050
Low
22.00
Averages
30.50
High
40.00
Current: 33.050
Low
22.00
Averages
30.50
High
40.00
About GLPG
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. It discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Galapagos Receives Transparency Notification from Bank of America
- Equity Change Notification: Galapagos received transparency notifications from Bank of America on February 27 and March 2, 2026, indicating that Bank of America and its controlled entity BofA Securities crossed the 5% voting rights threshold on February 26, 2026, highlighting significant interest in the company's equity.
- Shareholding Proportion Change: As of March 2, 2026, Bank of America and its affiliates owned 292,642 voting rights and 3,491,679 equivalent financial instruments, representing a total of 5.74% of Galapagos' current 65,897,071 shares, reflecting their important position in corporate governance.
- Voting Rights Dynamics: On February 27, 2026, BofA Securities fell below the 5% threshold again due to the disposal of financial instruments, demonstrating flexibility and dynamic adjustment in their holding strategy regarding Galapagos.
- Market Impact Analysis: This transparency notification not only reflects Bank of America's investment interest in Galapagos but may also influence market confidence in the company, prompting investors to monitor future changes in shareholding and their potential impact on stock prices.
See More
Galapagos Reports FY 2023 Financial Results with Significant Revenue Growth
- Strong Financial Performance: Galapagos reported a FY 2023 GAAP EPS of €4.87 and revenue of €1.11 billion, reflecting a remarkable 302.8% year-over-year growth, which enhances investor confidence and indicates robust market demand.
- Restructuring Cost Expectations: The company anticipates an operating cash outflow of up to €50 million in Q1 2026 due to the wind-down of cell therapy activities, with one-time restructuring cash impacts projected between €125 million and €175 million, a reduction of €25 million from previous guidance, showcasing proactive cost management.
- Ongoing R&D Investment: Galapagos expects cash costs of up to €40 million in 2026 for the TYK2 program, including the completion of Phase 2 clinical trials for DM and SLE, demonstrating the company's commitment to advancing critical research initiatives and preparing for Phase 3 development.
- Optimistic Cash Flow Outlook: The company projects to be cash flow neutral to positive by the end of 2026, excluding any business development activities or currency fluctuations, with anticipated cash and financial investments of approximately €2.775 billion to €2.850 billion, indicating strong financial health moving forward.
See More
Galapagos Set to Announce Q4 Earnings on February 23
- Earnings Announcement Schedule: Galapagos is set to release its Q4 2023 earnings report on February 23 before market open, with a consensus EPS estimate of $1.34, reflecting a 19.6% year-over-year improvement, indicating enhanced profitability.
- Revenue Expectations Decline: Despite the positive EPS outlook, the revenue estimate stands at $80.75 million, representing a significant 70.7% year-over-year decline, highlighting substantial challenges in revenue growth that may affect investor confidence.
- Strategic Shift: Galapagos is pivoting from clinical risk management to strategic capital allocation, aiming to optimize resource distribution to support the development of its rare autoimmune disease assets, demonstrating a commitment to future growth.
- Clinical Research Progress: The company has met its primary goal in a pivotal phase 3 study, which could bolster the market prospects for its rare disease treatment products and enhance investor confidence in its R&D capabilities.
See More
Bank of America Exceeds 5% Voting Rights in Galapagos
- Ownership Threshold Surpassed: Under Belgian transparency legislation, Bank of America crossed the 5% threshold of voting rights in Galapagos on February 9, 2026, reaching a total of 5.34%, indicating a strong commitment to the company.
- Voting Rights Breakdown: As of February 11, 2026, Bank of America and its affiliates held 104,522 voting rights and 3,415,894 equivalent financial instruments, enhancing their control over Galapagos and potentially influencing future corporate decisions.
- Transparency Notification: The notification from Bank of America, issued on February 11, 2026, reflects the changes in their shareholding, complying with Belgian legal requirements and providing clarity on their equity structure to the market.
- Market Implications: Bank of America's increased stake may heighten market interest in Galapagos, potentially driving stock price volatility and influencing other investors' decisions, reflecting growing confidence in the company's prospects.
See More
Vistra Corp Acquires Cogentrix Energy for Approximately $4.7 Billion
- Acquisition Announcement: Vistra Corp has announced the acquisition of Cogentrix Energy for approximately $4.7 billion, which will significantly enhance its competitive position in the energy market and expand its renewable energy portfolio.
- Market Reaction: Following the acquisition news, Vistra's stock rose by 4.13%, reflecting investor optimism regarding the company's future growth potential and further solidifying its position in the energy sector.
- Strategic Implications: This acquisition will not only increase Vistra's asset base but also enhance operational efficiency and market share through the integration of Cogentrix's resources and technologies, driving long-term profitability.
- Industry Outlook: Against the backdrop of global energy transition, Vistra's acquisition strategy indicates a commitment to sustainability, which is expected to attract more investor interest in its clean energy initiatives.
See More
Microchip Technology Raises Q3 FY2026 Sales Guidance to $1.185 Billion
- Sales Guidance Upgrade: Microchip Technology Inc expects third-quarter fiscal 2026 net sales of approximately $1.185 billion, exceeding its prior guidance range of $1.109 billion to $1.149 billion, indicating strong growth potential amid robust market demand.
- Positive Stock Reaction: In after-hours trading, Microchip's shares rose 3.2% to $69.20, reflecting investor optimism regarding the company's improved performance, which may further enhance market interest in its stock.
- Enhanced Market Competitiveness: With the sales guidance upgrade, Microchip solidifies its competitive position in the semiconductor industry, particularly in rapidly evolving technology sectors, attracting more investor attention.
- Upcoming Earnings Report: The company is set to release its earnings report after market close, with analysts expecting earnings of $1.04 per share and revenue of $761.13 million, providing investors with an opportunity to further assess the company's financial health.
See More
Galapagos Receives Transparency Notification from Bank of America
- Equity Change Notification: Galapagos received transparency notifications from Bank of America on February 27 and March 2, 2026, indicating that Bank of America and its controlled entity BofA Securities crossed the 5% voting rights threshold on February 26, 2026, highlighting significant interest in the company's equity.
- Shareholding Proportion Change: As of March 2, 2026, Bank of America and its affiliates owned 292,642 voting rights and 3,491,679 equivalent financial instruments, representing a total of 5.74% of Galapagos' current 65,897,071 shares, reflecting their important position in corporate governance.
- Voting Rights Dynamics: On February 27, 2026, BofA Securities fell below the 5% threshold again due to the disposal of financial instruments, demonstrating flexibility and dynamic adjustment in their holding strategy regarding Galapagos.
- Market Impact Analysis: This transparency notification not only reflects Bank of America's investment interest in Galapagos but may also influence market confidence in the company, prompting investors to monitor future changes in shareholding and their potential impact on stock prices.
See More
Galapagos Reports FY 2023 Financial Results with Significant Revenue Growth
- Strong Financial Performance: Galapagos reported a FY 2023 GAAP EPS of €4.87 and revenue of €1.11 billion, reflecting a remarkable 302.8% year-over-year growth, which enhances investor confidence and indicates robust market demand.
- Restructuring Cost Expectations: The company anticipates an operating cash outflow of up to €50 million in Q1 2026 due to the wind-down of cell therapy activities, with one-time restructuring cash impacts projected between €125 million and €175 million, a reduction of €25 million from previous guidance, showcasing proactive cost management.
- Ongoing R&D Investment: Galapagos expects cash costs of up to €40 million in 2026 for the TYK2 program, including the completion of Phase 2 clinical trials for DM and SLE, demonstrating the company's commitment to advancing critical research initiatives and preparing for Phase 3 development.
- Optimistic Cash Flow Outlook: The company projects to be cash flow neutral to positive by the end of 2026, excluding any business development activities or currency fluctuations, with anticipated cash and financial investments of approximately €2.775 billion to €2.850 billion, indicating strong financial health moving forward.
See More
Galapagos Set to Announce Q4 Earnings on February 23
- Earnings Announcement Schedule: Galapagos is set to release its Q4 2023 earnings report on February 23 before market open, with a consensus EPS estimate of $1.34, reflecting a 19.6% year-over-year improvement, indicating enhanced profitability.
- Revenue Expectations Decline: Despite the positive EPS outlook, the revenue estimate stands at $80.75 million, representing a significant 70.7% year-over-year decline, highlighting substantial challenges in revenue growth that may affect investor confidence.
- Strategic Shift: Galapagos is pivoting from clinical risk management to strategic capital allocation, aiming to optimize resource distribution to support the development of its rare autoimmune disease assets, demonstrating a commitment to future growth.
- Clinical Research Progress: The company has met its primary goal in a pivotal phase 3 study, which could bolster the market prospects for its rare disease treatment products and enhance investor confidence in its R&D capabilities.
See More
Bank of America Exceeds 5% Voting Rights in Galapagos
- Ownership Threshold Surpassed: Under Belgian transparency legislation, Bank of America crossed the 5% threshold of voting rights in Galapagos on February 9, 2026, reaching a total of 5.34%, indicating a strong commitment to the company.
- Voting Rights Breakdown: As of February 11, 2026, Bank of America and its affiliates held 104,522 voting rights and 3,415,894 equivalent financial instruments, enhancing their control over Galapagos and potentially influencing future corporate decisions.
- Transparency Notification: The notification from Bank of America, issued on February 11, 2026, reflects the changes in their shareholding, complying with Belgian legal requirements and providing clarity on their equity structure to the market.
- Market Implications: Bank of America's increased stake may heighten market interest in Galapagos, potentially driving stock price volatility and influencing other investors' decisions, reflecting growing confidence in the company's prospects.
See More
Vistra Corp Acquires Cogentrix Energy for Approximately $4.7 Billion
- Acquisition Announcement: Vistra Corp has announced the acquisition of Cogentrix Energy for approximately $4.7 billion, which will significantly enhance its competitive position in the energy market and expand its renewable energy portfolio.
- Market Reaction: Following the acquisition news, Vistra's stock rose by 4.13%, reflecting investor optimism regarding the company's future growth potential and further solidifying its position in the energy sector.
- Strategic Implications: This acquisition will not only increase Vistra's asset base but also enhance operational efficiency and market share through the integration of Cogentrix's resources and technologies, driving long-term profitability.
- Industry Outlook: Against the backdrop of global energy transition, Vistra's acquisition strategy indicates a commitment to sustainability, which is expected to attract more investor interest in its clean energy initiatives.
See More
Microchip Technology Raises Q3 FY2026 Sales Guidance to $1.185 Billion
- Sales Guidance Upgrade: Microchip Technology Inc expects third-quarter fiscal 2026 net sales of approximately $1.185 billion, exceeding its prior guidance range of $1.109 billion to $1.149 billion, indicating strong growth potential amid robust market demand.
- Positive Stock Reaction: In after-hours trading, Microchip's shares rose 3.2% to $69.20, reflecting investor optimism regarding the company's improved performance, which may further enhance market interest in its stock.
- Enhanced Market Competitiveness: With the sales guidance upgrade, Microchip solidifies its competitive position in the semiconductor industry, particularly in rapidly evolving technology sectors, attracting more investor attention.
- Upcoming Earnings Report: The company is set to release its earnings report after market close, with analysts expecting earnings of $1.04 per share and revenue of $761.13 million, providing investors with an opportunity to further assess the company's financial health.
See More
